INHIBITION OF STRUCTURAL JOINT DAMAGE WITH UPADACITINIB AS MONOTHERAPY OR IN COMBINATION WITH MTX IN PATRIENTS WITH RA: ONE-YEAR OUTCOMES FROM THE SELECT PHASE 3 PROGRAMME Peterfy, C., Genovese, M. C., Song, I., Friedman, A., Hall, S., Mysler, E., Durez, P., Baraliakos, X., Enejosa, J., Shaw, T., Li, Y., Chen, S., Strand, V. OXFORD UNIV PRESS. 2020

View details for Web of Science ID 000534330300187